Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00463606 · ClinicalTrials.gov registry record · Phase 3
A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 760
- Enrollment target
NCT00463606 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 760 participants.
The verdict
NCT00463606, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 760 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia.
Interventions
- DRUG ABT-335
- DRUG rosuvastatin calcium
- DRUG ABT-335 and rosuvastatin calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 760 participants |
| Start Date | 2007-04 |
| Est. Completion | 2008-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00463606
The ClinicalTrials.gov registry entry for NCT00463606 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 760 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ABT-335 is the first listed.
NCT00463606 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00463606 about?
NCT00463606 is a clinical study titled "A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia". The purpose of this study is to evaluate the safety and efficacy of ABT-335 and rosuvastatin calcium combination therapy to monotherapy in subjects with dyslipidemia.
What is the current status of trial NCT00463606?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 760 participants. The study started on 2007-04. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00463606?
The interventions under investigation include: ABT-335 (DRUG), rosuvastatin calcium (DRUG), ABT-335 and rosuvastatin calcium (DRUG).
Who is sponsoring clinical trial NCT00463606?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.